AC
NERV icon

Ascend Capital’s Minerva Neurosciences NERV Stock Holding History

Ascend Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-102,418
Closed -$4.96M – 250
2017
Q4 		$4.96M Buy
102,418
+4,707
+5% +$233K 0.19% 121
2017
Q3 		$5.94M Buy
+97,711
New +$5.6M 0.22% 104

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Ascend Capital's NERV Position: Q1 2018 in Review

Ascend Capital sold out of Minerva Neurosciences (NERV) in Q1 2018, closing a stake of 102,418 shares — an estimated $4.96M sold.

Ascend Capital first reported a position in NERV in Q3 2017 and held it in 2 quarters. The position peaked at $5.94M in Q3 2017. 67 funds tracked by Wall St. Rank hold NERV as of Q1 2018.

  • Ascend Capital reported no remaining Minerva Neurosciences position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 102,418 Minerva Neurosciences shares in Q1 2018, an estimated $4.96M.
  • Ascend Capital first reported a position in Minerva Neurosciences in Q3 2017 and held it in 2 quarters.
  • Ascend Capital's Minerva Neurosciences position peaked at $5.94M in Q3 2017.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.